{"protocolSection":{"identificationModule":{"nctId":"NCT04681482","orgStudyIdInfo":{"id":"B0661162"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare","officialTitle":"Effectiveness and Safety of Oral Anticoagulants Among Obese Patients With Non-Valvular Atrial Fibrillation in the Veterans Affairs Population With Medicare"},"statusModule":{"statusVerifiedDate":"2023-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-11-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-11-03","type":"ACTUAL"},"completionDateStruct":{"date":"2020-11-03","type":"ACTUAL"},"studyFirstSubmitDate":"2020-12-18","studyFirstSubmitQcDate":"2020-12-18","studyFirstPostDateStruct":{"date":"2020-12-23","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-10-28","resultsFirstSubmitQcDate":"2021-10-28","resultsFirstPostDateStruct":{"date":"2021-12-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-05-18","lastUpdatePostDateStruct":{"date":"2023-05-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who initiate therapy with OACs (oral anti-coagulants). The aim of this study is to compare all DOACs (direct oral anti-coagulants) to warfarin.\n\nHowever, the primary analysis will be conducted among apixaban vs warfarin patients only. If sample size permits, we will also conduct other DOAC vs warfarin and DOAC vs DOAC analysis."},"conditionsModule":{"conditions":["Atrial Fibrillation","Obesity","Anticoagulants"],"keywords":["Medicare","Veterans Affairs","Major Bleeding","Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":107383,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Apixaban Group","description":"The cohort prescribed apixaban and diagnosed with Atrial Fibrillation","interventionNames":["Drug: Apixaban"]},{"label":"Warfarin Group","description":"patients prescribed warfarin only diagnosed with Atrial Fibrillation."}],"interventions":[{"type":"DRUG","name":"Apixaban","description":"Anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation.","armGroupLabels":["Apixaban Group"],"otherNames":["Eliquis"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Event Rate Per 100 Participant-Years For First Occurrence of Major Bleeding Events After Index Date in Obese Participants","description":"Event rate per 100 participant-years for first occurrence of major bleeding (MB) event after index date in obese participants was reported. MB after index date was identified using hospital claims and occurred anytime during the follow-up period of drug use or within 30 days from the last day of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017 \\[3.5 years\\]). The first warfarin prescription date was designated as the index date for participants without any DOAC claim. MB events included the composite of gastrointestinal (GI), intracranial hemorrhage (ICH), and other sites. MB was equal to 1 if bleeding event was greater than equal to (\\>=) 1.","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)"},{"measure":"Event Rate Per 100 Participant-Years For First Occurrence of Major Bleeding Events After Index Date in Morbidly Obese Participants","description":"Event rate per 100 participant-years for first occurrence of MB event after index date in morbidly obese participants was reported. MB after index date was identified using hospital claims and occurred anytime during the follow-up period of drug use or within 30 days from the last day of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017). The first warfarin prescription date was designated as the index date for participants without any DOAC claim. MB events included the composite of GI, ICH, and other sites. MB was equal to 1 if bleeding event was \\>=1.","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)"},{"measure":"Event Rate Per 100 Participant-Years For First Occurrence of Stroke or Systemic Embolism (SE) Events After Index Date in Obese Participants","description":"Event rate per 100 participant-years for first occurrence of stroke or SE events after index date in obese participants was reported. Stroke/SE were identified using hospital claims and occurred anytime during the period of drug use or within 30 days from the last day of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017). The first warfarin prescription date was designated as the index date for participants without any DOAC claim. Stroke events included the composite of any ischemic, any hemorrhagic and SE stroke events. Stroke/SE was equal to 1 if stroke event was \\>=1.","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)"},{"measure":"Event Rate Per 100 Participant-Years For First Occurrence of Stroke or Systemic Embolism (SE) Events After Index Date in Morbidly Obese Participants","description":"Event rate per 100 participant-years for first occurrence of stroke or SE events after index date in morbidly obese participants was reported. Stroke/SE were identified using hospital claims and occurred anytime during the period of drug use or within 30 days from the last day of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017). The first warfarin prescription date was designated as the index date for participants without any DOAC claim. Stroke events included the composite of any ischemic, any hemorrhagic and SE stroke events. Stroke/SE was equal to 1 if stroke event was \\>=1.","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)"},{"measure":"Event Rate Per 100 Participant-Years For First Occurrence of Net Clinical Benefit After Index Date in Obese Participants","description":"Event rate per 100 participant-years for first occurrence of net clinical benefit after index date in obese participants was reported. For participants with stroke/SE or MB event, net clinical benefit was assessed by evaluating the first hospital claim for a stroke/SE or MB event. The hospital claim occurred anytime during the period of drug use or within 30 days from the last day of supply of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017). The first warfarin prescription date was designated as the index date for participants without any DOAC claim.","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)"},{"measure":"Event Rate Per 100 Participant-Years For First Occurrence of Net Clinical Benefit After Index Date in Morbidly Obese Participants","description":"Event rate per 100 participant-years for first occurrence of net clinical benefit after index date in morbidly obese participants was reported. For participants with stroke/SE or MB event, net clinical benefit was assessed by evaluating the first hospital claim for a stroke/SE or MB event. The hospital claim occurred anytime during the period of drug use or within 30 days from the last day of supply of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017). The first warfarin prescription date was designated as the index date for participants without any DOAC claim.","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)"},{"measure":"Charlson Comorbidity Index (CCI)","description":"CCI based on various comorbid conditions such as myocardial infarction, CHF, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, diabetes (mild to moderate), diabetes + complications, hemiplegia or paraplegia, renal disease, any malignancy (lymphoma and leukemia), moderate/severe liver disease, metastatic solid tumor, and acquired immune deficiency syndrome (AIDS) were reported. CCI score range was from 0 to 14, where \"0\"= low comorbid condition and \"14\"= high comorbid condition, higher scores indicated more comorbidity.","timeFrame":"Baseline (6 months prior to index date)"}],"secondaryOutcomes":[{"measure":"Time in Therapeutic Range (TTR) During Follow-up Period","description":"TTR was computed using INR values among warfarin participants during the follow-up. TTR was calculated based on the percentage of time a participant remained in therapeutic range evaluated during the entire follow-up period. TTR \\>=65 percent (%) was observed as good and TTR less than (\\<) 65% was observed as poor.","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Obese or severely obese.\n* Initiated an OAC from July 1, 2013 - December 31, 2017; the first DOAC pharmacy claim date during the identification period will be designated as the index date. The first warfarin prescription date will be designated as the index date for patients without any DOAC claim.\n* Individuals ≥18 years old as of the index date.\n* Had 6 months continuous health plan enrollment with medical benefits (Parts A \\& B) for at least 6 months pre-index date (baseline period).\n* At least 1 diagnosis of AF prior to or on index date, identified by any medical claim associated with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code of 427.31 or International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code of I480-I482, and I4891.\n* Had body weight or BMI value reported within ±6 months of the index date.\n\nExclusion Criteria:\n\n* Had medical claims indicating a diagnosis or procedure of rheumatic mitral valvular heart disease, heart valve replacement/transplant, venous thromboembolism, or transient AF 6 months prior to or on the index date.\n* Had hip/knee replacement surgery within 6 weeks prior to or on the index date.\n* Were pregnant during the study period.\n* Had an OAC prescription during the 6 months pre-index date.\n* Had follow-up time equal to 0 days.\n* Had more than one OAC on the index date.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Obese or severely obese AF patients in the CMS Medicare and Veterans' Health Affairs (VHA) databases who were newly prescribed OACs between January 1, 2013 and December 31, 2017.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Pfizer","city":"New York","state":"New York","zip":"10012","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}}]},"referencesModule":{"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=B0661162"}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"In this study, inverse probability of treatment weighted (IPTW) method was used in analysis of outcome measures to balance participant's characteristics among reporting groups. Baseline for this study was 6 months prior to the index date. The index date was the date of first prescription for an OAC (Warfarin) or DOAC (Apixaban, Dabigatran, and Rivaroxaban) pharmacy claim during the identification period from July 1, 2013 -December 31, 2017.","recruitmentDetails":"This was a retrospective population-based registry study. Data for participants diagnosed with non-valvular atrial fibrillation (NVAF) and treated with either oral anticoagulants (OAC \\[Warfarin\\]) or direct oral anticoagulants (DOAC \\[Apixaban, Dabigatran and Rivaroxaban\\]) retrieved from the Veterans Affairs (VA) Population and Centre for Medicare and Medicare Services (CMS) database from January 2013 to December 2017.","groups":[{"id":"FG000","title":"Warfarin","description":"Participants diagnosed with NVAF, who initiated warfarin on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first warfarin prescription for participants without any DOAC claim."},{"id":"FG001","title":"Apixaban","description":"Participants diagnosed with NVAF, who initiated apixaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."},{"id":"FG002","title":"Dabigatran","description":"Participants diagnosed with NVAF, who initiated dabigatran on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."},{"id":"FG003","title":"Rivaroxaban","description":"Participants diagnosed with NVAF, who initiated rivaroxaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"35051"},{"groupId":"FG001","numSubjects":"38756"},{"groupId":"FG002","numSubjects":"12148"},{"groupId":"FG003","numSubjects":"21428"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"35051"},{"groupId":"FG001","numSubjects":"38756"},{"groupId":"FG002","numSubjects":"12148"},{"groupId":"FG003","numSubjects":"21428"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Analysis population included obese or morbidly obese atrial fibrillation (AF) participants in the CMS and VA databases with newly prescribed OACs or DOACs between January 1, 2013 and December 31, 2017.","groups":[{"id":"BG000","title":"Warfarin","description":"Participants diagnosed with NVAF, who initiated warfarin on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first warfarin prescription for participants without any DOAC claim."},{"id":"BG001","title":"Apixaban","description":"Participants diagnosed with NVAF, who initiated apixaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."},{"id":"BG002","title":"Dabigatran","description":"Participants diagnosed with NVAF, who initiated dabigatran on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."},{"id":"BG003","title":"Rivaroxaban","description":"Participants diagnosed with NVAF, who initiated rivaroxaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"title":"18-54 years","measurements":[{"groupId":"BG000","value":"182"},{"groupId":"BG001","value":"94"},{"groupId":"BG002","value":"88"},{"groupId":"BG003","value":"105"},{"groupId":"BG004","value":"469"}]},{"title":"55-64 years","measurements":[{"groupId":"BG000","value":"1380"},{"groupId":"BG001","value":"833"},{"groupId":"BG002","value":"580"},{"groupId":"BG003","value":"827"},{"groupId":"BG004","value":"3620"}]},{"title":"65-74 years","measurements":[{"groupId":"BG000","value":"12410"},{"groupId":"BG001","value":"13037"},{"groupId":"BG002","value":"6873"},{"groupId":"BG003","value":"10070"},{"groupId":"BG004","value":"42390"}]},{"title":"75-79 years","measurements":[{"groupId":"BG000","value":"5817"},{"groupId":"BG001","value":"6504"},{"groupId":"BG002","value":"1741"},{"groupId":"BG003","value":"3472"},{"groupId":"BG004","value":"17534"}]},{"title":">=80 years","measurements":[{"groupId":"BG000","value":"15262"},{"groupId":"BG001","value":"18288"},{"groupId":"BG002","value":"2866"},{"groupId":"BG003","value":"6954"},{"groupId":"BG004","value":"43370"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"456"},{"groupId":"BG001","value":"576"},{"groupId":"BG002","value":"139"},{"groupId":"BG003","value":"299"},{"groupId":"BG004","value":"1470"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"34595"},{"groupId":"BG001","value":"38180"},{"groupId":"BG002","value":"12009"},{"groupId":"BG003","value":"21129"},{"groupId":"BG004","value":"105913"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2086"},{"groupId":"BG001","value":"2024"},{"groupId":"BG002","value":"621"},{"groupId":"BG003","value":"1172"},{"groupId":"BG004","value":"5903"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"32246"},{"groupId":"BG001","value":"35847"},{"groupId":"BG002","value":"11184"},{"groupId":"BG003","value":"19732"},{"groupId":"BG004","value":"99009"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"529"},{"groupId":"BG001","value":"654"},{"groupId":"BG002","value":"220"},{"groupId":"BG003","value":"343"},{"groupId":"BG004","value":"1746"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"190"},{"groupId":"BG001","value":"231"},{"groupId":"BG002","value":"123"},{"groupId":"BG003","value":"181"},{"groupId":"BG004","value":"725"}]}]}]},{"title":"Number of Participants From Different Regions of United States","description":"In this baseline measure, number of participants from different regions of the United States were reported. The United States was divided into 5 regions: northeast, midwest, south, west, and other/unknown.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"title":"Northeast","measurements":[{"groupId":"BG000","value":"7016"},{"groupId":"BG001","value":"6821"},{"groupId":"BG002","value":"1887"},{"groupId":"BG003","value":"3718"},{"groupId":"BG004","value":"19442"}]},{"title":"Midwest","measurements":[{"groupId":"BG000","value":"10498"},{"groupId":"BG001","value":"10046"},{"groupId":"BG002","value":"3008"},{"groupId":"BG003","value":"5858"},{"groupId":"BG004","value":"29410"}]},{"title":"South","measurements":[{"groupId":"BG000","value":"11809"},{"groupId":"BG001","value":"15311"},{"groupId":"BG002","value":"5080"},{"groupId":"BG003","value":"8398"},{"groupId":"BG004","value":"40598"}]},{"title":"West","measurements":[{"groupId":"BG000","value":"5576"},{"groupId":"BG001","value":"6392"},{"groupId":"BG002","value":"2134"},{"groupId":"BG003","value":"3361"},{"groupId":"BG004","value":"17463"}]},{"title":"Other/Unknown","measurements":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"186"},{"groupId":"BG002","value":"39"},{"groupId":"BG003","value":"93"},{"groupId":"BG004","value":"470"}]}]}]},{"title":"Number of Participants Classified According to OAC Index Year","description":"In this baseline measure, number of participants were classified according to the index year in which they received OAC. Index year was defined as the year (2013-2017) in which the treatment was initiated for the participants.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"title":"2013","measurements":[{"groupId":"BG000","value":"5090"},{"groupId":"BG001","value":"395"},{"groupId":"BG002","value":"974"},{"groupId":"BG003","value":"1135"},{"groupId":"BG004","value":"7594"}]},{"title":"2014","measurements":[{"groupId":"BG000","value":"9024"},{"groupId":"BG001","value":"2548"},{"groupId":"BG002","value":"2462"},{"groupId":"BG003","value":"3996"},{"groupId":"BG004","value":"18030"}]},{"title":"2015","measurements":[{"groupId":"BG000","value":"7770"},{"groupId":"BG001","value":"6792"},{"groupId":"BG002","value":"2178"},{"groupId":"BG003","value":"4370"},{"groupId":"BG004","value":"21110"}]},{"title":"2016","measurements":[{"groupId":"BG000","value":"7289"},{"groupId":"BG001","value":"12705"},{"groupId":"BG002","value":"3336"},{"groupId":"BG003","value":"5600"},{"groupId":"BG004","value":"28930"}]},{"title":"2017","measurements":[{"groupId":"BG000","value":"5878"},{"groupId":"BG001","value":"16316"},{"groupId":"BG002","value":"3198"},{"groupId":"BG003","value":"6327"},{"groupId":"BG004","value":"31719"}]}]}]},{"title":"Dose of the Index DOAC","description":"In this baseline measure, number of participants received a standard dose (apixaban - 5 milligram \\[mg\\], dabigatran - 150 mg, and rivaroxaban - 20 mg); a lower dose (apixaban - 2.5 mg, dabigatran - 75 mg, and rivaroxaban - 15 mg/10 mg); and other dose (rivaroxaban - 10 mg, dabigatran - 110 mg) based on initial prescription of DOAC were reported.","populationDescription":"No participant for reporting arm 'warfarin' had dose of DOAC at index date, hence, for this reporting group no data was collected and reported.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"72332"}]}],"categories":[{"title":"Standard Dose (5 mg Apixaban, 150 mg Dabigatran, 20 mg Rivaroxaban)","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"30494"},{"groupId":"BG002","value":"11411"},{"groupId":"BG003","value":"16108"},{"groupId":"BG004","value":"58013"}]},{"title":"Lower Dose (2.5 mg Apixaban, 75 mg Dabigatran, 15 mg Rivaroxaban)","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"8262"},{"groupId":"BG002","value":"726"},{"groupId":"BG003","value":"4550"},{"groupId":"BG004","value":"13538"}]},{"title":"Other Dose (10 mg Rivaroxaban , 110 mg Dabigatran)","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"770"},{"groupId":"BG004","value":"781"}]}]}]},{"title":"Body Weight","description":"In this baseline measure, number of participants with body weight in kilogram (Kg) were reported within +/- 6 months from the index date.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"title":"<=60 Kg","measurements":[{"groupId":"BG000","value":"871"},{"groupId":"BG001","value":"1009"},{"groupId":"BG002","value":"149"},{"groupId":"BG003","value":"359"},{"groupId":"BG004","value":"2388"}]},{"title":"61-99 Kg","measurements":[{"groupId":"BG000","value":"22449"},{"groupId":"BG001","value":"25698"},{"groupId":"BG002","value":"6924"},{"groupId":"BG003","value":"13225"},{"groupId":"BG004","value":"68296"}]},{"title":"100-119 Kg","measurements":[{"groupId":"BG000","value":"7102"},{"groupId":"BG001","value":"7830"},{"groupId":"BG002","value":"3094"},{"groupId":"BG003","value":"4776"},{"groupId":"BG004","value":"22802"}]},{"title":">=120 Kg","measurements":[{"groupId":"BG000","value":"3714"},{"groupId":"BG001","value":"3261"},{"groupId":"BG002","value":"1614"},{"groupId":"BG003","value":"2478"},{"groupId":"BG004","value":"11067"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"915"},{"groupId":"BG001","value":"958"},{"groupId":"BG002","value":"367"},{"groupId":"BG003","value":"590"},{"groupId":"BG004","value":"2830"}]}]}]},{"title":"Body Mass Index (BMI)","description":"In this baseline measure, number of participants with BMI in kilogram per square meters (kg/m\\^2) ranged from less than (\\<) 18.5 kg/m\\^2 to greater than (\\>) 40 kg/m\\^2 were reported within +/- 6 months from index date.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"title":"<18.5 kg/m^2","measurements":[{"groupId":"BG000","value":"285"},{"groupId":"BG001","value":"296"},{"groupId":"BG002","value":"47"},{"groupId":"BG003","value":"121"},{"groupId":"BG004","value":"749"}]},{"title":"(18.5-24.9) kg/m^2","measurements":[{"groupId":"BG000","value":"5921"},{"groupId":"BG001","value":"6890"},{"groupId":"BG002","value":"1586"},{"groupId":"BG003","value":"3158"},{"groupId":"BG004","value":"17555"}]},{"title":"(25-29) kg/m^2","measurements":[{"groupId":"BG000","value":"8803"},{"groupId":"BG001","value":"10490"},{"groupId":"BG002","value":"3041"},{"groupId":"BG003","value":"5563"},{"groupId":"BG004","value":"27897"}]},{"title":"(30-39) kg/m^2","measurements":[{"groupId":"BG000","value":"10293"},{"groupId":"BG001","value":"11425"},{"groupId":"BG002","value":"4357"},{"groupId":"BG003","value":"6923"},{"groupId":"BG004","value":"32998"}]},{"title":">40 kg/m^2","measurements":[{"groupId":"BG000","value":"2176"},{"groupId":"BG001","value":"1746"},{"groupId":"BG002","value":"896"},{"groupId":"BG003","value":"1294"},{"groupId":"BG004","value":"6112"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"7573"},{"groupId":"BG001","value":"7909"},{"groupId":"BG002","value":"2221"},{"groupId":"BG003","value":"4369"},{"groupId":"BG004","value":"22072"}]}]}]},{"title":"International Normalized Ratio (INR)","description":"In this baseline measure, number of participants with or without INR were reported.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"title":"Yes","measurements":[{"groupId":"BG000","value":"15304"},{"groupId":"BG001","value":"9133"},{"groupId":"BG002","value":"3561"},{"groupId":"BG003","value":"3977"},{"groupId":"BG004","value":"31975"}]},{"title":"No","measurements":[{"groupId":"BG000","value":"19747"},{"groupId":"BG001","value":"29623"},{"groupId":"BG002","value":"8587"},{"groupId":"BG003","value":"17451"},{"groupId":"BG004","value":"75408"}]}]}]},{"title":"CHADS2 Score","description":"In this baseline measure, CHADS2 score was assessed by combining score of 5 risk factors (congestive heart failure \\[CHF\\] history, hypertension history, age \\>=75 years, diabetes mellitus history and stroke symptoms previously). Score ranged from 0-6, where \"0\" indicates low risk and \"6\" indicates high risk, where higher scores indicated more risk.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"0","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"1424"},{"groupId":"BG001","value":"1506"},{"groupId":"BG002","value":"944"},{"groupId":"BG003","value":"1352"},{"groupId":"BG004","value":"5226"}]}]},{"title":"1","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"6829"},{"groupId":"BG001","value":"7280"},{"groupId":"BG002","value":"3640"},{"groupId":"BG003","value":"5413"},{"groupId":"BG004","value":"23162"}]}]},{"title":"2","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"11372"},{"groupId":"BG001","value":"12318"},{"groupId":"BG002","value":"3985"},{"groupId":"BG003","value":"6935"},{"groupId":"BG004","value":"34610"}]}]},{"title":">=3","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"15426"},{"groupId":"BG001","value":"17652"},{"groupId":"BG002","value":"3579"},{"groupId":"BG003","value":"7728"},{"groupId":"BG004","value":"44385"}]}]}]},{"title":"CHA2DS2-VASc Score","description":"In this baseline measure, CHA2DS2-VASc score was assessed by combining score of 8 risk factors (CHF, hypertension, age \\>=75 years, diabetes mellitus, stroke \\[non-hemorrhagic only and transient ischemic attack {TIA}\\], vascular disease \\[myocardial infarction, peripheral arterial disease, aortic plaque\\], age 65 to 74 years, and sex category). Score ranged from 0-9, where \"0\" indicates low risk and \"9\" indicates high risk, where higher scores indicated more risk.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"0","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"71"},{"groupId":"BG003","value":"87"},{"groupId":"BG004","value":"307"}]}]},{"title":"1","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"1280"},{"groupId":"BG001","value":"1405"},{"groupId":"BG002","value":"886"},{"groupId":"BG003","value":"1227"},{"groupId":"BG004","value":"4798"}]}]},{"title":"2","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"4703"},{"groupId":"BG001","value":"5764"},{"groupId":"BG002","value":"2709"},{"groupId":"BG003","value":"4007"},{"groupId":"BG004","value":"17183"}]}]},{"title":"3","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"8196"},{"groupId":"BG001","value":"9734"},{"groupId":"BG002","value":"3520"},{"groupId":"BG003","value":"5718"},{"groupId":"BG004","value":"27168"}]}]},{"title":">=4","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"20793"},{"groupId":"BG001","value":"21783"},{"groupId":"BG002","value":"4962"},{"groupId":"BG003","value":"10389"},{"groupId":"BG004","value":"57927"}]}]}]},{"title":"HAS-BLED Score","description":"In this baseline measure, HAS-BLED score was assessed by combining score of 8 risk factors (hypertension, abnormal kidney or/liver function, age \\>=75 years, stroke, bleeding, labile INR, age \\>65 years, and alcohol/drug therapy). Score ranged from 0-9, where \"0\" indicates low risk and \"9\" indicates high risk, where higher scores indicated more risk.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"0","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"135"},{"groupId":"BG001","value":"109"},{"groupId":"BG002","value":"83"},{"groupId":"BG003","value":"130"},{"groupId":"BG004","value":"457"}]}]},{"title":"1","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"3859"},{"groupId":"BG001","value":"4522"},{"groupId":"BG002","value":"1733"},{"groupId":"BG003","value":"2770"},{"groupId":"BG004","value":"12884"}]}]},{"title":"2","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"11444"},{"groupId":"BG001","value":"13675"},{"groupId":"BG002","value":"5457"},{"groupId":"BG003","value":"8533"},{"groupId":"BG004","value":"39109"}]}]},{"title":">=3","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"19613"},{"groupId":"BG001","value":"20450"},{"groupId":"BG002","value":"4875"},{"groupId":"BG003","value":"9995"},{"groupId":"BG004","value":"54933"}]}]}]},{"title":"Baseline Medication Use","description":"In this baseline measure, number of participants on medications prescribed at baseline were reported. Prescribed medications were angiotensin-converting enzyme (ACE) inhibitors/ angiotensin-receptor blockers (ARB), beta blockers, H2 receptor-antagonist, proton pump inhibitor, statins, anti-platelets, and non-steroidal anti inflammatory drugs (NSAIDS).","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"ACE/ARB","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"13562"},{"groupId":"BG001","value":"14295"},{"groupId":"BG002","value":"4777"},{"groupId":"BG003","value":"8049"},{"groupId":"BG004","value":"40683"}]}]},{"title":"Beta blockers","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"18486"},{"groupId":"BG001","value":"20198"},{"groupId":"BG002","value":"6177"},{"groupId":"BG003","value":"11211"},{"groupId":"BG004","value":"56072"}]}]},{"title":"H2-receptor antagonist","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"2268"},{"groupId":"BG001","value":"2584"},{"groupId":"BG002","value":"695"},{"groupId":"BG003","value":"1288"},{"groupId":"BG004","value":"6835"}]}]},{"title":"Proton pump inhibitor","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"12227"},{"groupId":"BG001","value":"13793"},{"groupId":"BG002","value":"3896"},{"groupId":"BG003","value":"7178"},{"groupId":"BG004","value":"37094"}]}]},{"title":"Statins","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"23095"},{"groupId":"BG001","value":"25830"},{"groupId":"BG002","value":"7959"},{"groupId":"BG003","value":"13901"},{"groupId":"BG004","value":"70785"}]}]},{"title":"Anti-platelets","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"8686"},{"groupId":"BG001","value":"10515"},{"groupId":"BG002","value":"2980"},{"groupId":"BG003","value":"5141"},{"groupId":"BG004","value":"27322"}]}]},{"title":"NSAIDS","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"3819"},{"groupId":"BG001","value":"5319"},{"groupId":"BG002","value":"1904"},{"groupId":"BG003","value":"3388"},{"groupId":"BG004","value":"14430"}]}]}]},{"title":"Bariatric Surgery","description":"In this baseline measure, number of participants with bariatric surgery at baseline were reported.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"130"},{"groupId":"BG001","value":"125"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"93"},{"groupId":"BG004","value":"391"}]}]}]},{"title":"Comorbid Conditions","description":"In this baseline measure, number of participants with various comorbid conditions such as bleeding history, CHF, diabetes mellitus, hypertension, renal disease, liver disease, myocardial infarction, dyspepsia or stomach discomfort, non-stroke/systemic embolism (SE) peripheral vascular disease, stroke/SE, TIA, anemia and coagulation defects, alcoholism, peripheral artery disease, and coronary artery disease were reported.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Bleeding History","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"6021"},{"groupId":"BG001","value":"5564"},{"groupId":"BG002","value":"1367"},{"groupId":"BG003","value":"2886"},{"groupId":"BG004","value":"15838"}]}]},{"title":"CHF","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"13188"},{"groupId":"BG001","value":"12385"},{"groupId":"BG002","value":"3025"},{"groupId":"BG003","value":"6062"},{"groupId":"BG004","value":"34660"}]}]},{"title":"Diabetes Mellitus","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"15527"},{"groupId":"BG001","value":"15225"},{"groupId":"BG002","value":"4714"},{"groupId":"BG003","value":"8453"},{"groupId":"BG004","value":"43919"}]}]},{"title":"Hypertension","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"29689"},{"groupId":"BG001","value":"32639"},{"groupId":"BG002","value":"10117"},{"groupId":"BG003","value":"17961"},{"groupId":"BG004","value":"90406"}]}]},{"title":"Renal Disease","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"4540"},{"groupId":"BG001","value":"8022"},{"groupId":"BG002","value":"929"},{"groupId":"BG003","value":"2367"},{"groupId":"BG004","value":"15858"}]}]},{"title":"Liver Disease","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"1430"},{"groupId":"BG001","value":"1388"},{"groupId":"BG002","value":"418"},{"groupId":"BG003","value":"814"},{"groupId":"BG004","value":"4050"}]}]},{"title":"Myocardial Infarction","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"5344"},{"groupId":"BG001","value":"5628"},{"groupId":"BG002","value":"1200"},{"groupId":"BG003","value":"2841"},{"groupId":"BG004","value":"15013"}]}]},{"title":"Dyspepsia or Stomach Discomfort","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"4322"},{"groupId":"BG001","value":"4201"},{"groupId":"BG002","value":"1110"},{"groupId":"BG003","value":"2438"},{"groupId":"BG004","value":"12071"}]}]},{"title":"Non-stroke/SE Peripheral Vascular Disease","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"8994"},{"groupId":"BG001","value":"9560"},{"groupId":"BG002","value":"2276"},{"groupId":"BG003","value":"4836"},{"groupId":"BG004","value":"25666"}]}]},{"title":"Stroke/SE","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"4468"},{"groupId":"BG001","value":"4731"},{"groupId":"BG002","value":"1062"},{"groupId":"BG003","value":"2186"},{"groupId":"BG004","value":"12447"}]}]},{"title":"TIA","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"2750"},{"groupId":"BG001","value":"4508"},{"groupId":"BG002","value":"840"},{"groupId":"BG003","value":"1807"},{"groupId":"BG004","value":"9905"}]}]},{"title":"Anemia and Coagulation Defects","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"10572"},{"groupId":"BG001","value":"9987"},{"groupId":"BG002","value":"2129"},{"groupId":"BG003","value":"4640"},{"groupId":"BG004","value":"27328"}]}]},{"title":"Alcoholism","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"11323"},{"groupId":"BG001","value":"14181"},{"groupId":"BG002","value":"4241"},{"groupId":"BG003","value":"7567"},{"groupId":"BG004","value":"37312"}]}]},{"title":"Peripheral Artery Disease","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"8817"},{"groupId":"BG001","value":"8927"},{"groupId":"BG002","value":"2156"},{"groupId":"BG003","value":"4610"},{"groupId":"BG004","value":"24510"}]}]},{"title":"Coronary Artery Disease","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35051"},{"groupId":"BG001","value":"38756"},{"groupId":"BG002","value":"12148"},{"groupId":"BG003","value":"21428"},{"groupId":"BG004","value":"107383"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"19283"},{"groupId":"BG001","value":"21041"},{"groupId":"BG002","value":"5664"},{"groupId":"BG003","value":"10903"},{"groupId":"BG004","value":"56891"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Event Rate Per 100 Participant-Years For First Occurrence of Major Bleeding Events After Index Date in Obese Participants","description":"Event rate per 100 participant-years for first occurrence of major bleeding (MB) event after index date in obese participants was reported. MB after index date was identified using hospital claims and occurred anytime during the follow-up period of drug use or within 30 days from the last day of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017 \\[3.5 years\\]). The first warfarin prescription date was designated as the index date for participants without any DOAC claim. MB events included the composite of gastrointestinal (GI), intracranial hemorrhage (ICH), and other sites. MB was equal to 1 if bleeding event was greater than equal to (\\>=) 1.","populationDescription":"Obese participants with or without DOAC treatment diagnosed with NVAF were included in the outcome measure. Analysis performed using IPTW method to balance participant characteristics among reporting groups.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events Per 100 Participant-Years","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)","groups":[{"id":"OG000","title":"Warfarin","description":"Participants diagnosed with NVAF, who initiated warfarin on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first warfarin prescription for participants without any DOAC claim."},{"id":"OG001","title":"Apixaban","description":"Participants diagnosed with NVAF, who initiated apixaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12918"},{"groupId":"OG001","value":"13604"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.27"},{"groupId":"OG001","value":"4.06"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cox Proportional Hazards Model was used to compare the risk of MB between cohorts.","nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Model","paramType":"Hazard Ratio (HR)","paramValue":"0.62","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.54","ciUpperLimit":"0.70"}]},{"type":"PRIMARY","title":"Event Rate Per 100 Participant-Years For First Occurrence of Major Bleeding Events After Index Date in Morbidly Obese Participants","description":"Event rate per 100 participant-years for first occurrence of MB event after index date in morbidly obese participants was reported. MB after index date was identified using hospital claims and occurred anytime during the follow-up period of drug use or within 30 days from the last day of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017). The first warfarin prescription date was designated as the index date for participants without any DOAC claim. MB events included the composite of GI, ICH, and other sites. MB was equal to 1 if bleeding event was \\>=1.","populationDescription":"Morbidly obese participants with or without DOAC treatment diagnosed with NVAF were included in the outcome measure. Analysis performed using IPTW method to balance participant characteristics among reporting groups.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events Per 100 Participant-Years","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)","groups":[{"id":"OG000","title":"Warfarin","description":"Participants diagnosed with NVAF, who initiated warfarin on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first warfarin prescription for participants without any DOAC claim."},{"id":"OG001","title":"Apixaban","description":"Participants diagnosed with NVAF, who initiated apixaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2176"},{"groupId":"OG001","value":"1746"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.52"},{"groupId":"OG001","value":"3.94"}]}]}]},{"type":"PRIMARY","title":"Event Rate Per 100 Participant-Years For First Occurrence of Stroke or Systemic Embolism (SE) Events After Index Date in Obese Participants","description":"Event rate per 100 participant-years for first occurrence of stroke or SE events after index date in obese participants was reported. Stroke/SE were identified using hospital claims and occurred anytime during the period of drug use or within 30 days from the last day of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017). The first warfarin prescription date was designated as the index date for participants without any DOAC claim. Stroke events included the composite of any ischemic, any hemorrhagic and SE stroke events. Stroke/SE was equal to 1 if stroke event was \\>=1.","populationDescription":"Obese participants with or without DOAC treatment diagnosed with NVAF were included in this outcome measure. Analysis performed using IPTW method to balance participant characteristics among reporting groups.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events Per 100 Participant-Years","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)","groups":[{"id":"OG000","title":"Warfarin","description":"Participants diagnosed with NVAF, who initiated warfarin on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first warfarin prescription for participants without any DOAC claim."},{"id":"OG001","title":"Apixaban","description":"Participants diagnosed with NVAF, who initiated apixaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12918"},{"groupId":"OG001","value":"13604"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09"},{"groupId":"OG001","value":"1.51"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cox Proportional Hazards Model was used to compare the risk of stroke/SE between cohorts.","nonInferiorityType":"SUPERIORITY","pValue":"0.088","statisticalMethod":"Cox Proportional Hazards Model","paramType":"Hazard Ratio (HR)","paramValue":"0.82","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.66","ciUpperLimit":"1.03"}]},{"type":"PRIMARY","title":"Event Rate Per 100 Participant-Years For First Occurrence of Stroke or Systemic Embolism (SE) Events After Index Date in Morbidly Obese Participants","description":"Event rate per 100 participant-years for first occurrence of stroke or SE events after index date in morbidly obese participants was reported. Stroke/SE were identified using hospital claims and occurred anytime during the period of drug use or within 30 days from the last day of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017). The first warfarin prescription date was designated as the index date for participants without any DOAC claim. Stroke events included the composite of any ischemic, any hemorrhagic and SE stroke events. Stroke/SE was equal to 1 if stroke event was \\>=1.","populationDescription":"Morbidly obese participants with or without DOAC treatment diagnosed with NVAF were included in this outcome measure. Analysis performed using IPTW method to balance participant characteristics among reporting groups.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events Per 100 Participant-Years","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)","groups":[{"id":"OG000","title":"Warfarin","description":"Participants diagnosed with NVAF, who initiated warfarin on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first warfarin prescription for participants without any DOAC claim."},{"id":"OG001","title":"Apixaban","description":"Participants diagnosed with NVAF, who initiated apixaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2176"},{"groupId":"OG001","value":"1746"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.51"},{"groupId":"OG001","value":"0.92"}]}]}]},{"type":"PRIMARY","title":"Event Rate Per 100 Participant-Years For First Occurrence of Net Clinical Benefit After Index Date in Obese Participants","description":"Event rate per 100 participant-years for first occurrence of net clinical benefit after index date in obese participants was reported. For participants with stroke/SE or MB event, net clinical benefit was assessed by evaluating the first hospital claim for a stroke/SE or MB event. The hospital claim occurred anytime during the period of drug use or within 30 days from the last day of supply of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017). The first warfarin prescription date was designated as the index date for participants without any DOAC claim.","populationDescription":"Obese participants with or without DOAC treatment diagnosed with NVAF were included in this outcome measure. Analysis performed using IPTW method to balance participant characteristics among reporting groups.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Event Rate Per 100 Participant-Years","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)","groups":[{"id":"OG000","title":"Warfarin","description":"Participants diagnosed with NVAF, who initiated warfarin on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first warfarin prescription for participants without any DOAC claim."},{"id":"OG001","title":"Apixaban","description":"Participants diagnosed with NVAF, who initiated apixaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12918"},{"groupId":"OG001","value":"13604"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.44"},{"groupId":"OG001","value":"5.12"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cox Proportional Hazards Model was used to compare the risk of net clinical benefit between cohorts.","nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Model","paramType":"Hazard Ratio (HR)","paramValue":"0.67","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.60","ciUpperLimit":"0.76"}]},{"type":"PRIMARY","title":"Event Rate Per 100 Participant-Years For First Occurrence of Net Clinical Benefit After Index Date in Morbidly Obese Participants","description":"Event rate per 100 participant-years for first occurrence of net clinical benefit after index date in morbidly obese participants was reported. For participants with stroke/SE or MB event, net clinical benefit was assessed by evaluating the first hospital claim for a stroke/SE or MB event. The hospital claim occurred anytime during the period of drug use or within 30 days from the last day of supply of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017). The first warfarin prescription date was designated as the index date for participants without any DOAC claim.","populationDescription":"Morbidly obese participants with or without DOAC treatment diagnosed with NVAF were included in this outcome measure. Analysis performed using IPTW method to balance participant characteristics among reporting groups.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Event Rate Per 100 Participant-Years","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)","groups":[{"id":"OG000","title":"Warfarin","description":"Participants diagnosed with NVAF, who initiated warfarin on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first warfarin prescription for participants without any DOAC claim."},{"id":"OG001","title":"Apixaban","description":"Participants diagnosed with NVAF, who initiated apixaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2176"},{"groupId":"OG001","value":"1746"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.48"},{"groupId":"OG001","value":"4.52"}]}]}]},{"type":"PRIMARY","title":"Charlson Comorbidity Index (CCI)","description":"CCI based on various comorbid conditions such as myocardial infarction, CHF, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, diabetes (mild to moderate), diabetes + complications, hemiplegia or paraplegia, renal disease, any malignancy (lymphoma and leukemia), moderate/severe liver disease, metastatic solid tumor, and acquired immune deficiency syndrome (AIDS) were reported. CCI score range was from 0 to 14, where \"0\"= low comorbid condition and \"14\"= high comorbid condition, higher scores indicated more comorbidity.","populationDescription":"Analysis population included obese or morbidly obese AF participants in the CMS and VA databases with newly prescribed OACs or DOACs between January 1, 2013 and December 31, 2017.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on a scale","timeFrame":"Baseline (6 months prior to index date)","groups":[{"id":"OG000","title":"Warfarin","description":"Participants diagnosed with NVAF, who initiated warfarin on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first warfarin prescription for participants without any DOAC claim."},{"id":"OG001","title":"Apixaban","description":"Participants diagnosed with NVAF, who initiated apixaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."},{"id":"OG002","title":"Dabigatran","description":"Participants diagnosed with NVAF, who initiated dabigatran on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."},{"id":"OG003","title":"Rivaroxaban","description":"Participants diagnosed with NVAF, who initiated rivaroxaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35051"},{"groupId":"OG001","value":"38756"},{"groupId":"OG002","value":"12148"},{"groupId":"OG003","value":"21428"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.13","spread":"2.68"},{"groupId":"OG001","value":"2.55","spread":"2.39"},{"groupId":"OG002","value":"2.21","spread":"2.18"},{"groupId":"OG003","value":"2.49","spread":"2.37"}]}]}]},{"type":"SECONDARY","title":"Time in Therapeutic Range (TTR) During Follow-up Period","description":"TTR was computed using INR values among warfarin participants during the follow-up. TTR was calculated based on the percentage of time a participant remained in therapeutic range evaluated during the entire follow-up period. TTR \\>=65 percent (%) was observed as good and TTR less than (\\<) 65% was observed as poor.","populationDescription":"TTR was calculated only for the warfarin arm, therefore data was not collected/observed for DOACs cohorts - apixaban, dabigatran, rivaroxaban.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Percentage of time","timeFrame":"From first dose of study drug to follow-up period or within 30 days from last prescription date (data collected and observed retrospectively for 3.5 years)","groups":[{"id":"OG000","title":"Warfarin","description":"Participants diagnosed with NVAF, who initiated warfarin on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first warfarin prescription for participants without any DOAC claim."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35051"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","lowerLimit":"0","upperLimit":"1461"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","description":"Due to observational nature of study, minimum criteria for reporting adverse events did not met, hence adverse events were not collected","eventGroups":[{"id":"EG000","title":"Warfarin","description":"Participants diagnosed with NVAF, who initiated warfarin on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first warfarin prescription for participants without any DOAC claim.","deathsNumAffected":0,"deathsNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0},{"id":"EG001","title":"Apixaban","description":"Participants diagnosed with NVAF, who initiated apixaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017).","deathsNumAffected":0,"deathsNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0},{"id":"EG002","title":"Dabigatran","description":"Participants diagnosed with NVAF, who initiated dabigatran on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017).","deathsNumAffected":0,"deathsNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0},{"id":"EG003","title":"Rivaroxaban","description":"Participants diagnosed with NVAF, who initiated rivaroxaban on the index date, were included in this cohort and their data from July 2013 to December 2017, available in VA and CMS database observed retrospectively. Index date was defined as the date of the first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017).","deathsNumAffected":0,"deathsNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Data for Edoxaban drug cohort was not observed due to small sample size, based on Sponsor's decision. Data for creatinine clearance was not recorded and reported due to insufficient amount of data."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2020-09-14","uploadDate":"2021-10-28T16:24","filename":"Prot_SAP_000.pdf","size":23274050}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M12391","name":"Obesity","relevance":"LOW"},{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9246","name":"Hemorrhage","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000522181","term":"Apixaban"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M288142","name":"Apixaban","asFound":"Extraction","relevance":"HIGH"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M17292","name":"Warfarin","relevance":"LOW"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":true}